Business / Finance

RSS

Caris Life Sciences to facilitate patient access to tumour profiling service in Middle East and Africa

Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of personalized medicine in oncology, has signed a distribution agreement with IPS Genomix to facilitate patient access to its tumour profiling service, Molecular Intelligence, in select Middle Eastern and African markets.

22 Aug 2013

MicuRx Pharmaceuticals raises $25 million in Series B financing

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced it raised $25 million in Series B financing. Led by BVCF, a private equity and growth fund specializing in the life sciences industry, the round also includes existing investors Morningside Group and Devon Park Bioventures.

22 Aug 2013

Tel-Aviv Stock Exchange approves new listing of OPKO's common stock

OPKO Health, Inc. (NYSE: OPK), a multi-national biopharmaceutical and diagnostics company, today announced that the Tel-Aviv Stock Exchange ("TASE") has approved the new listing of OPKO's common stock on the TASE beginning on August 21, 2013, under the ticker symbol OPK. OPKO's common stock will thereafter be listed on both the NYSE in the United States and the TASE in Israel.

19 Aug 2013

Evogene announces financial results for second quarter and half year 2013

Evogene Ltd., a leader in plant genomics underlying crop productivity for the food, feed and biofuel industries, today announced its financial results for the second quarter and half year ended June 30, 2013.

19 Aug 2013

Illumina announces availability of its newest reagent kits for MiSeq benchtop sequencer

Illumina, Inc. today announced the availability of its newest reagent kits for the MiSeq, the industry's most accurate and easiest-to-use benchtop sequencer. The improved chemistry doubles sequencing output to 15 gigabases (Gb) by increasing the number of sequencing reads (up to 25 million reads) and overall read length (up to 2x300 base pairs). These innovations enable researchers to perform new applications including exome sequencing on the MiSeq.

From Illumina, Inc. 19 Aug 2013

Over 1,700 new chiral HPLC/SFC applications added to Phenomenex’s online resource

Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, announces the addition of over 1,700 new chiral HPLC/SFC applications to its online resource, including more than 400 new SFC (supercritical fluid chromatography) methods. Phenomenex’s extensive chiral application database is unique in the industry, particularly with the addition of the SFC methods, which were developed in collaboration with the Department of Analytical Chemistry and Pharmaceutical Technology, Vrije Universiteit Brussel, Brussels, Belgium.

19 Aug 2013

New UV-visible spectrophotometer released by Hitachi High Technologies America, Inc.

The Life Sciences Division of Hitachi High Technologies America, Inc. released its newest UV-visible spectrophotometer, Model UH5300.

16 Aug 2013

Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials

Boehringer Ingelheim today announced that enrolment of over 950 treatment naïve genotype-1b patients in the pivotal Phase III interferon-free HCVerso™ 1 and 2 trials is complete.

15 Aug 2013

RaySearch Laboratories announces first patient treated with RayStation

RaySearch Laboratories AB announces that the first patient in Australasia has been treated with a treatment plan created with RaySearch's treatment planning system RayStation®. The treatment was carried out at Auckland Radiation Oncology in Auckland, New Zealand.

From Elekta 13 Aug 2013

Precision Therapeutics continues its support to NOCC Pittsburgh Chapter

Precision Therapeutics will proudly continue its dedicated support to the NOCC Pittsburgh Chapter's 13th Annual Walk to Break the Silence on Ovarian Cancer. Precision has been a strong supporter of the NOCC 5 Mile Run/5 Mile & 1 Mile walk for over five years, and once again expects a great number of its employees will join together in full force to walk alongside ovarian cancer patients and survivors to help strengthen the partnerships it has forged by supporting the very cancer patients that it strives to help.

13 Aug 2013

Easton-Bell Sports announces financial results for second quarter 2013

Easton-Bell Sports, Inc. (the "Company"), a leading designer, developer and marketer of branded sports equipment, protective products and related accessories, today announced financial results for the second quarter ended June 29, 2013.

13 Aug 2013

Intercept Pharmaceuticals reports financial results for Second quarter 2013

Intercept Pharmaceuticals, Inc. (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, today reported financial results for the quarter and six months ended June 30, 2013 and announced presentations at an upcoming medical conference and upcoming investor conferences.

13 Aug 2013

Cyanotech announces first quarter financial results of fiscal year 2014

Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the first quarter of fiscal year 2014, ended June 30, 2013.

12 Aug 2013

Saint-Gobain introduces next-generation Tygon S3 tubing for use in laboratory applications

Saint-Gobain Performance Plastics, the maker of Tygon® high-performance flexible tubing, has become the first manufacturer to introduce a bio-based, phthalate-free product for use in laboratory applications. DEHP Di(2-ethylhexyl phthalate), a common plasticizer, has been removed from existing Tygon® formulations.

12 Aug 2013

Derma Sciences reports financial and operating results for 2013

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and six months ended June 30, 2013.

12 Aug 2013

MyFitnessPal closes $18 million Series to improve health and wellness of millions of users

MyFitnessPal, the leading free personal health and fitness system, today announced it has closed an $18 million Series A round of funding led by Kleiner Perkins Caufield & Byers with participation by Accel Partners. Both John Doerr and Andrew Braccia have also joined the company's board.

12 Aug 2013

Omeros announces financial results for second quarter of 2013

Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the second quarter of 2013.

12 Aug 2013

New reagent kits for intracellular staining from Beckman Coulter Life Sciences

PerFix-Expose1 and PerFix-nc1, innovative new reagent kits for intracellular staining from Beckman Coulter Life Sciences, minimize sample manipulation for a streamlined workflow that delivers high quality results. Developed for use on Beckman Coulter’s Gallios1 and Navios2 series flow cytometers and compatible with all Beckman Coulter Life Sciences’ fluorochromes, the kits enable a clear focus on the cytoplasmic and nuclear compartments of the cell.

8 Aug 2013

TruClinic signs new partnership with University of Utah Hospital's Department of Telemedicine

Today TruClinic announced a new partnership with University of Utah Hospital's Department of Telemedicine, which will enable patients and practitioners to have video-based online visits and consultations with simply a computing device, Internet connection and a webcam.

8 Aug 2013

FitBionic completes $2.2M funding round with KMG Capital Partners, CID4 and High Country Venture

FitBionic has completed a $2.2 million funding round with a team led by KMG Capital Partners, with High Country Venture and the Colorado Institute for Drug, Device and Diagnostic Development. The investment was developed in support of the global launch of FitBionic's currently available first product, the FitBionic Foot, and as a bridge to the company's Series A financing, which is expected in 2014.

8 Aug 2013

Business / Finance

Caris Life Sciences to facilitate patient access to tumour profiling service in Middle East and Africa

MicuRx Pharmaceuticals raises $25 million in Series B financing

Tel-Aviv Stock Exchange approves new listing of OPKO's common stock

Evogene announces financial results for second quarter and half year 2013

Illumina announces availability of its newest reagent kits for MiSeq benchtop sequencer

Over 1,700 new chiral HPLC/SFC applications added to Phenomenex’s online resource

New UV-visible spectrophotometer released by Hitachi High Technologies America, Inc.

Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials

RaySearch Laboratories announces first patient treated with RayStation

Precision Therapeutics continues its support to NOCC Pittsburgh Chapter

Easton-Bell Sports announces financial results for second quarter 2013

Intercept Pharmaceuticals reports financial results for Second quarter 2013

Cyanotech announces first quarter financial results of fiscal year 2014

Saint-Gobain introduces next-generation Tygon S3 tubing for use in laboratory applications

Derma Sciences reports financial and operating results for 2013

MyFitnessPal closes $18 million Series to improve health and wellness of millions of users

Omeros announces financial results for second quarter of 2013

New reagent kits for intracellular staining from Beckman Coulter Life Sciences

TruClinic signs new partnership with University of Utah Hospital's Department of Telemedicine

FitBionic completes $2.2M funding round with KMG Capital Partners, CID4 and High Country Venture

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News